ESM-1：一种新型肿瘤标志物及其研究进展。
ESM-1: A Novel Tumor Biomaker and its Research Advances.
机构信息
Qinghai University Graduate School, Xining, China.
Department of Haematology, The Affiliated Hospital of Qinghai University, Xining, China.
出版信息
Anticancer Agents Med Chem. 2019;19(14):1687-1694. doi: 10.2174/1871520619666190705151542.
BACKGROUND
Cancer kills nearly 9,000,000 people worldwide, and its mortality was reported up to 28% in the past decade. Few available tumor markers have been known to help early stage diagnosis. In this study, Endocan was taken as a novel tumor marker, which has been found in many cancers related to cancer cell proliferation, neoangiogenesis, etc. Methods: Studies on Endocan and its correlation with cancer were reviewed, and key points of meaningful studies on the structure, pathways and targeted agents of Endocan were drawn.
RESULTS
Endocan leads to tumorigenesis and promotes tumor cells proliferation HGF/SF signal transmission pathway, suppresses tumor cells apoptosis NF-κB signaling pathway and promotes angiogenesis within tumors VEGF and HIF pathway. Medicine suppressing the expression of Endocan could prevent tumorigenesis and even improve survival rate of mice with tumor significantly.
CONCLUSION
Endocan is capable of promoting prognosis of cancer patients. Moreover, Endocan is supposed to a potential target of tumor-targeted therapy.
背景
癌症在全球范围内导致近 900 万人死亡，在过去十年中，其死亡率据报道高达 28%。目前已知的少数肿瘤标志物有助于早期诊断。在这项研究中，Endocan 被作为一种新的肿瘤标志物，它已在许多与癌细胞增殖、新生血管生成等相关的癌症中被发现。
方法
对 Endocan 及其与癌症的相关性进行了研究，并对 Endocan 的结构、途径和靶向药物的有意义研究的要点进行了总结。
结果
Endocan 导致肿瘤发生并促进肿瘤细胞增殖 HGF/SF 信号转导途径，抑制肿瘤细胞凋亡 NF-κB 信号通路并促进肿瘤内血管生成 VEGF 和 HIF 通路。抑制 Endocan 表达的药物可以预防肿瘤发生，甚至显著提高荷瘤小鼠的生存率。
结论
Endocan 能够促进癌症患者的预后。此外，Endocan 有望成为肿瘤靶向治疗的潜在靶点。
Zotero 插件